Edison Investment Research - RCM Beteiligungs AG (A1RFMY) RCM Beteiligungs - Building strongly

Report

Edison Investment Research

Richard Finch

RCM Beteiligungs - Building strongly

RCM Beteiligungs continues to please with H119 PBT of â‚¬4.1m comfortably exceeding managementâ€™s guidance of an improvement in full-year PBT (â‚¬2.9m+). Although the driver may have been a bumper c â‚¬10m disposal in Q1, the second quarter also saw a y-o-y step-change in PBT, boosted by markedly lower finance costs thanks to interim reinvestment of asset sale proceeds. Even if 2019 guidance has not been updated, favourable macro factors and scope for efficiencies and asset development support RCMâ€™s positive outlook, as does its commitment to re-build its portfolio (both commercial and residential), as confirmed by two recent deals of size.

19/08/2019 3 EN

Underlying

RCM Beteiligungs AG

RCM Beteiligungs AG is a Germany-based investment company that invests in real estate and third companies. In the real estate segment, the Company focuses on residential real estate properties in Eastern Germany. The Company operates through SM Wirtschaftsberatung AG, SM Capital AG, SM Domestic Property AG, Krocker GmbH Dresden and Apollo Hausverwaltung GmbH Dresden.

See profile

DE000A1RFMY4 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Richard Finch

Other Reports on these Companies

EQS Group AG

EQS-News: Veröffentlichung der Geschäftszahlen für das Geschäftsjahr 2023 (HGB, testiert)

EQS-News: RCM Beteiligungs AG / Schlagwort(e): Jahresergebnis Veröffentlichung der Geschäftszahlen für das Geschäftsjahr 2023 (HGB, testiert) 29.02.2024 / 16:27 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Sindelfingen, den 29. Februar 2024 Corporate News Veröffentlichung der Geschäftszahlen für das Geschäftsjahr 2023 (HGB, testiert) Die RCM Beteiligungs AG hat das für den Immobilienmarkt herausfordernde Geschäftsjahr 2023 in ihrer Einzelgesellschaft mit einem leichten operativen Fehlbetrag von 0,17 Mio. Euro abgeschlossen. Das ...

February 29, 2024 February 29, 2024 1 DE

SmartInsider

RCM Beteiligungs AG: 1 director

A director at RCM Beteiligungs AG bought 20,000 shares at 1.495EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of...

Free Trial

December 13, 2023 December 13, 2023 1 EN

EQS Group AG

EQS-News: Geschäftszahlen der RCM Beteiligungs AG nach dem dritten Quartal des Geschäftsjahres 2023 (nicht testiert und nach HGB)

EQS-News: RCM Beteiligungs AG / Schlagwort(e): Quartalsergebnis/9-Monatszahlen Geschäftszahlen der RCM Beteiligungs AG nach dem dritten Quartal des Geschäftsjahres 2023 (nicht testiert und nach HGB) 24.10.2023 / 14:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Sindelfingen, den 24. Oktober 2023 Corporate News Geschäftszahlen der RCM Beteiligungs AG nach dem dritten Quartal des Geschäftsjahres 2023 (nicht testiert und nach HGB) Die RCM Beteiligungs AG weist ihr Konzernergebnis aus der gewöhnlichen Geschäftstätigkeit (HGB, untes...

October 24, 2023 October 24, 2023 1 DE

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol c 220 patients with cognitive impairment (CI) associated with biomarker-positive mild-to-moderate Alzheimer’s disease (AD), as confirmed through an elevated level of phosphorylated Tau-181 (pTau-181) protein in their blood at baseline. The study has commenced at 13 Australian sites and will concentrate on domestic sites for the first c 100 patients, and initial efficacy and safety results will b...

2h / 37m 2h / 37m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subje...

2h / 58m 2h / 58m 1 EN

Pedro Fonseca

Pedro Fonseca

Tetragon Financial Group - FY23 growth driven by idiosyncratic factors

Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return (TR) in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 performance was below the 26.3% return of the S&P 500 Index, which rallied on the artificial intelligence (AI) theme. Tetragon’s FY23 return on equity (RoE) of 5.5% was below its target of 10–15% pa. That said, its performance since listing was within the target range at 11.3%. Tetragon continues payouts to its shareholders, distributing US$83.6m in FY23 through buybacks an...

4h / 8m 4h / 8m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN